Extramedullary Disease

News

January 09, 2025

2 min read

Save

Combination induces durable responses in advanced multiple myeloma

The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.